Neutralizing antibody responses, breakthrough SARS-CoV-2 infections, and symptoms after booster BNT162b2 COVID-19 vaccinations

A new study evaluated neutralizing antibody (nAb) responses against the SARS-CoV-2 Omicron variant induced by booster vaccination with Pfizer-BioNTech’s BNT162b2 messenger ribonucleic acid vaccine.